

# Exchange transfusion for neonatal hyperbilirubinemia: A multicenter, prospective study of Turkish Neonatal Society

Emel Okulu<sup>1</sup>, Ömer Erdeve<sup>1</sup>, Oğuz Tuncer<sup>2</sup>, Sabahattin Ertuğrul<sup>3</sup>, Hülya Özdemir<sup>4</sup>, Nukhet Aladağ Çiftdemir<sup>5</sup>, Ayşegül Zenciroğlu<sup>6</sup>, Begüm Atasay<sup>1</sup>; on behalf of Turkish Neonatal Society Exchange Transfusion Study Group\*

<sup>1</sup>Department of Pediatrics, Division of Neonatology, Ankara University Faculty of Medicine, Ankara, Turkey

<sup>2</sup>Department of Pediatrics, Division of Neonatology, Yüzüncü Yıl University Faculty of Medicine, Van, Turkey

<sup>3</sup>Department of Pediatrics, Division of Neonatology, Dicle University Faculty of Medicine, Diyarbakır, Turkey

<sup>4</sup>Department of Pediatrics, Division of Neonatology, Marmara University Faculty of Medicine, İstanbul, Turkey

<sup>5</sup>Department of Pediatrics, Division of Neonatology, Trakya University Faculty of Medicine, Edirne, Turkey

<sup>6</sup>Department of Neonatology, Dr. Sami Ulus Gynecology Obstetrics and Child Health and Diseases Training and Research Hospital, University of Health Sciences, Ankara, Turkey

## What is already known on this topic?

- Exchange transfusion has declined in recent years but is still performed in many countries.
- The procedure is associated with considerable complications.

## What this study adds on this topic?

- This is the first prospective, population-based study of infants with hyperbilirubinemia who underwent exchange transfusion in our country.
- Proper protocols for screening, follow-up, and management of hyperbilirubinemia need to be enforced.

## ABSTRACT

**Objective:** The frequency of neonatal exchange transfusion has declined in recent years, but is still performed in many countries. The procedure is associated with complications. The aim of the study was to determine the clinical features and etiologies of infants with hyperbilirubinemia who underwent exchange transfusion and evaluate the adverse events and clinical outcomes.

**Material and Methods:** We performed a secondary analysis of the multicenter Turkish Neonatal Jaundice Online Registry data. Otherwise healthy newborns born  $\geq 35$  weeks of gestation who were hospitalized for jaundice and underwent exchange transfusion were included.

**Results:** One-hundred thirty-two patients with a mean serum bilirubin level on admission of  $24.9 \pm 9.1$  mg/dL were enrolled in the study. The most common cause for exchange transfusion was hemolytic jaundice (63.6%), followed by lack of proper feeding (12.9%). It was found that the infants with lack of proper feeding were discharged earlier from the maternity ward ( $p=0.02$ ), but they were admitted to hospital later ( $p<0.001$ ) with a higher bilirubin level ( $p=0.001$ ), and greater weight loss ( $p=0.04$ ). The reported rate of adverse events associated with exchange transfusion was 11.4%. The most common complication was thrombocytopenia (40%). None of the infants died during the procedure. Acute bilirubin encephalopathy was reported in 13 (9.8%) patients.

**Conclusion:** Severe hyperbilirubinemia requiring exchange transfusion and acute bilirubin encephalopathy are still challenging problems in neonatal period in our country. The policies including blood group analysis of pregnant women, programs informing parents about breastfeeding and jaundice, and monitoring bilirubin levels of high-risk newborns should be developed to reduce the necessitating for exchange transfusion and to avoid related complications.

**Keywords:** Complication, exchange transfusion, hyperbilirubinemia, newborn

## Corresponding Author:

Emel Okulu

✉ emelokulu@gmail.com

Received: 09.03.2020

Accepted: 29.09.2020

Available Online Date: 06.01.2021

turkarchpediatr.org

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



## Introduction

Exchange transfusion (ET) is the removal of an infant's blood with high bilirubin levels and/or antibody-coated red blood cells (RBCs) and replacement with fresh donor blood. It is indicated when hyperbilirubinemia remains at high levels despite intensive phototherapy and is particularly useful when there is excessive hemolysis. Another indication for ET is moderate-severe acute bilirubin encephalopathy (ABE), regardless of the bilirubin level at the time (1, 2). Although the frequency of neonatal ET has declined markedly in the last two decades,

**Cite this article as:** Okulu E, Erdeve Ö, Tuncer O, et al. Exchange transfusion for neonatal hyperbilirubinemia: A multicenter, prospective study of Turkish Neonatal Society. Turk Arch Pediatr 2021; 56(2): 121-6.

which is associated with the widespread use of intensive phototherapy, anti-D prophylaxis use for Rh-negative mothers, intravenous immunoglobulin (IVIg) use in infants with hemolysis, and advances in prenatal and postnatal care, this procedure is still performed in many countries, especially in those with a high incidence of severe hyperbilirubinemia (3-5).

However, ET is not a risk-free procedure. Adverse events associated with ET have been reported even in settings with advanced clinical care. It may be associated with complications such as sepsis, electrolyte imbalance, air embolism, portal vein thrombosis, cardiac overload, thrombophlebitis, thrombocytopenia, necrotizing enterocolitis, the transmission of blood-borne diseases, and even mortality (6-10).

The aim of this study was to determine the clinical features and etiologies of infants with hyperbilirubinemia who required ET, to evaluate the complications related to the procedure, adverse clinical outcomes associated with hyperbilirubinemia, and to try to define new recommendations to prevent these.

## Material and Methods

This study used the data of the 132 patients who were enrolled in the Turkish Neonatal Jaundice Online Registry, which was a multicenter prospective cohort study conducted between September 2015 and September 2016 at 50 neonatal intensive care units (NICUs) to evaluate neonatal jaundice in our country. The full details of this study have been published elsewhere (11).

Otherwise healthy newborns born  $\geq 35$  weeks of gestation who were hospitalized for jaundice and underwent ET were included in the study. The data of infants from 20 collaborating NICUs were evaluated. Patients were managed according to the unit protocols based on the guidelines for neonatal jaundice (2, 12).

A standardized electronic case form including details about the demographic and clinical findings of infants was created on an online registry database with a separate sheet for each patient. Basic patient characteristics including the gestational age (GA), birth weight (BW), sex, history of phototherapy or ET in siblings, age on admission to hospital, type of delivery, age of admission, weight loss on admission, maximum level of total bilirubin at the time of ET (mg/dL), hemoglobin (g/dL), reticulocyte count (%), and bilirubin/albumin ratio were recorded. The cut-off values for reticulocyte count and bilirubin/albumin were taken as 7% and 6.5, respectively, according to the data found in our published study (11).

The causes of hyperbilirubinemia were classified as follows: Rh incompatibility was defined as jaundice with the presence of hemolysis (direct Coombs positivity, low hematocrit and elevated reticulocyte count) in Rh-positive neonate from Rh-negative mother. Hemolytic disease due to ABO incompatibility was defined as the presence of jaundice, elevated reticulocyte count, a peripheral smear suggestive of hemolysis, anemia with or without direct Coombs positivity in a neonate with blood group A or B from a mother with blood group O. Minor blood group incompatibility was defined as alloimmunization due to minor erythrocyte non-D Rh antigens (c, C, e, E, Kell, Duffy, Kidd, and MNS) with direct Coombs positivity (13).

Lack of proper feeding was diagnosed by the physician with the following: weight loss  $\geq 10\%$  on the third day of life, diminished urine/stool output, and confirmed dehydration with laboratory tests. Glucose-6-phosphate dehydrogenase (G6PD) deficiency was diagnosed by measuring the enzyme activity using quantitative spectrophotometric analysis (14). Polycythemia was defined as a venous hematocrit  $\geq 65\%$  in an infant without signs of dehydration (15).

The double-volume ET procedure (160-180 mL/kg) was generally completed by repeatedly removing and replacing small aliquots of blood (5-7 mL/kg) in about 60-120 minutes through a single catheter in the umbilical vein or a catheter each in the umbilical vein and umbilical artery or a catheter placed in a peripheral vessel. Whole blood or RBCs plus fresh frozen plasma (FFP) was used for ET according to the unit's preference and availability of the product. The ETs were performed by the attending neonatologists or neonatology fellow or by pediatric residents.

The adverse events associated with the procedure were defined as any complication occurring within 7 days of an ET. The following definitions were used for adverse events: thrombocytopenia for a platelet count of  $< 100\,000/\text{mm}^3$ , hypocalcemia for serum calcium level of  $< 8$  mg/dL, necrotizing enterocolitis defined according to the modified Bell's criteria (16).

Adverse clinical outcomes associated with hyperbilirubinemia were evaluated. The bilirubin-induced neurologic dysfunction (BIND) score was used to define ABE (17). All patients underwent auditory evaluations to determine the auditory brainstem response before discharge from NICUs, and repeat tests were performed in the following months. Prolonged jaundice was defined as persisting jaundice  $> 14$  days for term infants,  $> 21$  days for preterm infants (born  $< 37$  gestational weeks') (18). Re-admission was defined as infants who returned to the hospital within 0-20 days of initial discharge (19).

The study was approved by Online Studies Scientific Steering Committee of Turkish Neonatal Society, and ethics committee approval was obtained from Ankara University Faculty of Medicine, Clinical Researches Ethics Committee (Approval No. 14-593-15). The study was conducted in accordance with the Declaration of Helsinki and informed consent was obtained from all participants.

## Statistical analysis

All data were analyzed using the IBM Statistical Packages for the Social Sciences (IBM SPSS Corp.; Armonk, NY, USA) Ver. 21.0 software package. Categorical data are presented as number (n) and percentage (%). Continuous variables are presented as mean  $\pm$  standard deviation. Student's t-test was used to compare the groups showed normal distribution. A p-value at the 0.05 level was considered statistically significant.

## Results

During the study period, 5620 infants were recorded at 'Turkish Neonatal Jaundice Online Registry', and 132 of these infants (2.3%) underwent ET. The total number of admissions of the 20 collaborating NICUs was 24 899 during this period.

The infants had a mean GA and BW of 38±1.5 weeks and 3005±480 g, respectively. The male to female ratio was 1.4:1. All infants were hospital-born. The mean age of the infants at discharge from the maternity ward and on admission to the NICU

for jaundice was 2.9±1.6 days and 3.7±2.5 days, respectively. The mean total serum bilirubin level on admission was 24.9±9.1 mg/dL, and almost half of the infants (49.3%) were admitted with a bilirubin level of >25 mg/dL. The demographic and laboratory findings of the patients are shown in Table 1.

**Table 1. Demographic and laboratory findings of patients underwent exchange transfusion**

	Number of patients (n=132)
Gestational age (w)*	38±1.5
Birth weight (g)*	3005±480
Sex (male), n (%)	77 (58.3)
Type of delivery (CS), n (%)	53 (40.1)
Sibling with history of phototherapy, n (%)	28 (21.2)
Sibling with history of ET, n (%)	6 (4.5)
Age at discharge from maternity service (d) *	2.9±1.6
Age on admission (d)*, §	3.7±2.5 3.5 (1-9)
Weight loss rate on admission (%)*	4.5±5.2
≤10% loss, n (%)	112 (85)
>10% loss, n (%)	20 (15)
Bilirubin level on admission (mg/dL)*	24.9±9.1
<20 mg/dL, n (%)	35 (26.5)
20-25 mg/dL, n (%)	32 (24.2)
26-30 mg/dL, n (%)	27 (20.5)
>30 mg/dL, n (%)	38 (28.8)
Hemoglobin on admission (g/dL)*	14±4.2
Direct coombs positivity, n (%)	55 (41.7)
Reticulocyte count*	6.4±5.8
<7, n (%)	63 (47.7)
≥7, n (%)	37 (28)
Not recorded	32 (24)
Albumin level (g/dL) *	3.4±0.5
Bilirubin/albumin ratio <6.5, n (%)	39 (29.5)
Bilirubin/albumin ratio ≥6.5, n (%)	63 (47.7)
Not recorded	30 (22.8)

\*Data reported as mean±standard deviation, §Data reported as median (range). CS, Cesarean section; ET, Exchange transfusion

**Table 2. Causes of hemolytic jaundice**

Causes	Number of patients (n=15)
ABO incompatibility, n (%)	37 (44)
Rh incompatibility, n (%)	34 (40.5)
Minor blood group incompatibility, n (%)	9 (10.7)
G6PD deficiency, n (%)	4 (4.8)

G6PD, Glucose-6-phosphate dehydrogenase

**Table 3. Adverse events associated with exchange transfusion procedure**

	No. of patients (n=15)
Thrombocytopenia, n (%)	6 (40)
Hypocalcemia, n (%)	3 (20)
Hypocalcemia+thrombocytopenia, n (%)	2 (13.3)
Necrotizing enterocolitis, n (%)	2 (13.3)
Hypocalcemia+thrombocytopenia+sepsis, n (%)	1 (6.7)
Sepsis, n (%)	1 (6.7)


The most common cause for ET was hemolytic jaundice (63.6%), followed by a lack of proper feeding (12.9%), prematurity (4.5%), polycythemia (3%), cephalohematoma (1.5%), and sepsis (0.75%). No underlying condition could be found in 13.6% of cases (Figure 1). Among the hemolytic jaundice cases, ABO blood incompatibility was the leading etiology (44%) (Table 2). Among the 80 infants with hemolytic jaundice due to ABO blood, Rh or minor blood group incompatibility, 39 infants received IVIG before ET.

The infants with a lack of proper feeding (n=17) were discharged earlier from the maternity ward after birth (2.4±0.9 vs. 3.1±1.7 days, p=0.02), but were admitted to the NICU later (5.9±2.2 vs. 3±2.3 days, p<0.001) with a higher mean weight loss (8.5±6.1 vs. 3.5±4.6, p=0.04) and a higher bilirubin level on admission (30.1±6.4 vs. 23±9.4 mg/dL, p=0.001) when compared with infants who had hemolytic jaundice (n=84). Almost half of the patients (47%) with a lack of proper feeding had severe dehydration (>10% weight loss).

Exchange transfusion was performed via a single catheter in the umbilical vein in 124 (94%) patients, a catheter each in the umbilical vein and umbilical artery in five (4%) patients, and a substitute catheter placed in a peripheral vein in three (2%) patients. Although whole blood was used in 59 (44.7%) patients, RBCs plus FFP was preferred in 73 (55.3%) infants for the ET procedure. Adverse events associated with ET were seen in 15 patients (11.4%) (Table 3). The most commonly observed complication was thrombocytopenia (40%). None of the infants died during the ET procedure.

**Table 4. Adverse clinical outcomes of infants who underwent exchange transfusion**

	Number of patients (n=132)
Acute bilirubin encephalopathy, n (%)	13 (9.8)
Prolonged jaundice, n (%)	12 (9.1)
Hearing loss, n (%)	7 (5.3)
Rehospitalization, n (%)	2 (1.5)
Without problem, n (%)	98 (74.2)



**Figure 1.** Etiologies of infants who underwent exchange transfusion

The adverse clinical outcomes reported in patients who underwent ET are listed in Table 4. ABE was reported in 13 infants (9.8%), 11 (84.6%) of whom were male. The median BIND score of infants who had ABE was 7 (range 4-9) days. Patients with ABE had a mean admission age as  $4\pm 1.2$  days and mean serum bilirubin level of  $35.9\pm 5.7$  mg/dL, whereas infants who did not develop ABE had a mean serum bilirubin level of  $23.8\pm 8.6$  mg/dL ( $p<0.001$ ). The etiologies of infants with ABE were reported as hemolytic jaundice in ( $n=8$ , 61.5%), lack of proper feeding ( $n=2$ , 7.7%), and unknown cause ( $n=3$ , 23.1%), respectively. Two of these patients died in the NICU on the postnatal 8<sup>th</sup> and 9<sup>th</sup> days of their lives.

## Discussion

Exchange transfusion is a definitive and an effective therapy where intensive phototherapy is either lacking or proves to be ineffective in arresting rising bilirubin levels in infants with severe neonatal hyperbilirubinemia or symptoms of ABE (2, 20, 21). Through this study, we determined the incidence and the underlying causes of patients who underwent ET, adverse events associated with ET, and adverse clinical outcomes associated with hyperbilirubinemia. Although the findings presented here are already known about this procedure, some specific implications for our country were obtained with the data of this study.

ABO hemolytic disease of the newborn was the leading cause of hyperbilirubinemia in patients who underwent ET in our cohort, similar to that reported in many series (22-25). On the other hand, this study showed that rhesus disease was the second most common cause of hemolytic jaundice, responsible for 25.7% of all ETs. Despite anti-D prophylaxis being provided free by the state, rhesus disease is still a common cause of alloimmunization in our country. In a study from Turkey, the prevalence of Rh alloimmunization was found as 8.7% in the Rh-negative group (26).

One of the important results of the study was the lack of proper feeding, which was the second most common cause of ET. Cesarean section (CS) delivery in Turkey is above the suggested rate by the World Health Organization, which may contribute to a lack of proper breastfeeding with early discharge from maternity wards (27). Poor caloric intake, dehydration associated with decreased volume and frequency, and the secondary delayed passage of stools due to inadequate breastfeeding may contribute to the development of hyperbilirubinemia (3). Studies showed that woman who delivered by CS were less likely to breastfeed, or there was a delay in breastfeeding initiation (28, 29). Although it is recommended to discharge mothers after three days following CS by health organization, it is a common practice to discharge mothers on the second day after birth. It was demonstrated that discharge after 24 hours following CS resulted in higher neonatal admission with jaundice compared with the group discharged after 72 hours (30). Earlier discharge of neonates from maternity wards may result in infants leaving close supervision before breastfeeding was successfully established and before clinically apparent jaundice could become manifest (31). We believe that late initiation of effective breastfeeding, short hospital stay in the maternity ward after birth, inadequate establishment of breastfeeding, and incon-

sistent follow-up after discharge may all be factors in the high rate of severe hyperbilirubinemia requiring ET in our country.

The ET procedure is relatively safe when performed by experienced practitioners in newborns (8, 9). Central umbilical catheter or peripheral veins are used for ET to remove and replace the infant's blood (6). The pull-push technique through a central umbilical catheter (98%) was used mostly with RBCs and FFP (55.3%) in this study. Although Yigit et al. (32) demonstrated that the use of O group RBCs suspended in A or B plasma decreased the re-exchange risk compared with O group whole blood in cases of ABO hemolytic disease, the same efficiency was shown with using either reconstituted or fresh whole blood for ET (33). As whole blood contains natural anti-A or anti-B antibodies, group O Rh-specific RBCs reconstituted with AB plasma are recommended in ABO incompatibility. If mother and infant are ABO identical, group-specific RBCs or whole blood can be used (34). Adverse events associated ET were reported at different rates from centers. The reported adverse events in our study were similar to previous reports in the literature (5, 7-9). Although mortality was reported in a few series, we did not observe any deaths associated with ET in our study.

Most neonatal jaundice cases are benign, but in some cases, serum bilirubin level may rise excessively and can cause serious complications, such as acute encephalopathy. Cases of kernicterus continue to be reported worldwide. Neonates with hemolytic disease seem to be at higher risk of bilirubin-induced brain damage than non-hemolytic neonates (35-37). Lack of recognition and treatment of jaundice, and failure of the healthcare system could be represented with increased incidence of high bilirubin levels. Although our study was not designed to access the incidence of long-term neurologic problems, 13 (9.8%) infants developed ABE, and the most common cause of hyperbilirubinemia in these infants was hemolytic disease. It has been demonstrated that measuring bilirubin level before discharge is helpful to predict which infants will exhibit jaundice (38). We could likely prevent more severe hyperbilirubinemia requiring ET in addition to bilirubin encephalopathy if all centers performed a bilirubin test on all neonates before discharge and planned follow-up.

This study includes the first multicenter, online nationwide information on ET from our country. The data reported in a registry database was largely drawn from NICUs of tertiary centers across Turkey where neonatologists are aware of the situation, and therefore the information can be generalized to a national level. The limitation of this study is the dependence on self-reported data, which may lead to underestimating the exact incidence and data of severe hyperbilirubinemia and ABE.

The results of this study demonstrate that hyperbilirubinemia requiring ET and bilirubin encephalopathy are still problems in our country. Although hemolysis is the major cause of hyperbilirubinemia in infants needing ET, the other important factors are early discharge from maternity ward after birth without establishing appropriate breastfeeding, insufficient feeding, under-recognition of jaundice by parents, and late presentation to hospital. Simple policies for blood group analysis of pregnant women, breastfeeding consultations through postnatal care, bilirubin monitoring of newborns before discharge from



the maternity ward, and health education of the population about jaundice can identify infants with high risk and help to prevent severe hyperbilirubinemia related short and long-term complications.

**Ethical Committee Approval:** The study was approved by Online Studies Scientific Steering Committee of Turkish Neonatal Society, and the ethic committee approval was obtained from Ankara University Faculty of Medicine, Clinical Researches Ethics Committee (Approval No. 14-593-15).

**Informed Consent:** Written informed consent was obtained from all participants who participated in this study.

**Peer-review:** Externally peer-reviewed.

**Authorship Contributions:** Concept – Ö.E., E.O.; Design – E.O., Ö.E.; Supervision – A.Z., B.A.; Data Collection and/or Processing – E.O., O.T., S.E., H.Ö., N.A.Ç.; Analysis and/or Interpretation – E.O., Ö.E., O.T., B.A.; Literature Review – E.O., Ö.E.; Writing – E.O.; Critical Review – Ö.E., B.A.

**Conflict of Interest:** The authors of have no conflicts of interest, including specific financial interests, relationships and/or affiliations relevant to the subject matter or materials included.

**Acknowledgements:** We thank to Turkish Neonatal Society for funding the project, to all collaborator NICUs and the investigators, as the members of the Exchange Transfusion Study Group\*. The following investigators are the members of the Turkish Neonatal Society Exchange Transfusion Study Group: Saadet Arsan (Ankara University Faculty of Medicine, Ankara), Deniz Hanta (Adana Gynecology and Obstetrics and Children's Hospital, Adana), Ramazan Ozdemir (Inonu University Faculty of Medicine, Malatya), Beril Yasa (Istanbul University Faculty of Medicine, Istanbul), Bilge Tanyeri Bayraktar (Bezmialem University Faculty of Medicine, Istanbul), Gokhan Buyukkale (Kanuni Training and Research Hospital, Istanbul), Berna Hekimoglu (Kanuni Training and Research Hospital, Trabzon), Nilufer Guzoglu (Kirikkale University Faculty of Medicine, Kirikkale), Ayse Engin Arsoy (Kocaeli University Faculty of Medicine, Kocaeli), Elif Ozyazıcı (Ondokuz Mayıs University Faculty of Medicine, Samsun), Ozge Aydemir (Osmangazi University Faculty of Medicine, Eskisehir), Akan Yaman (Sanliurfa Gynecology and Obstetrics Hospital, Sanliurfa), Hilal Ozkan (Uludag University Faculty of Medicine, Bursa), Leyla Bilgin (Umraniye Research and Training Hospital, Istanbul), Evrim Alyamac Dizdar (Zekai Tahir Burak Maternity Teaching Hospital, Ankara).

## References

- Practice parameter: management of hyperbilirubinemia in the healthy term newborn. American Academy of Pediatrics and Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. *Pediatrics* 1994; 94: 558-65.
- American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics* 2004; 114: 297-316. [Crossref]
- Monpoux F, Dageville C, Mailotte AM, De Semet S, Casagrande F, Boutte P. High-dose intravenous immunoglobulin therapy and neonatal jaundice due to red blood cell alloimmunization. *Arch Pediatr* 2009; 16: 91289-94. [Crossref]
- Duplantie J, Gonzales OM, Bois A, et al. Cost-effectiveness of the management of Rh-negative pregnant women. *J Obstet Gynaecol Can* 2013; 35: 730-40. [Crossref]
- Steiner LA, Bizzarro MJ, Ehrankranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. *Pediatrics* 2007; 120: 27-32. [Crossref]
- Salas AA, Mazzi E. Exchange transfusions in infants with extreme hyperbilirubinemia: an experience from a developing country. *Acta Paediatr* 2008; 97: 754-8. [Crossref]
- Murki S, Kumar P. Blood exchange transfusion for infants with severe neonatal hyperbilirubinemia. *Semin Perinatol* 2011; 35: 175-84. [Crossref]
- Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. *Pediatrics* 1997; 99: E7. [Crossref]
- Keenan WJ, Novak KK, Sutherland JM, Bryla DA, Fetterly KL. Morbidity and mortality associated with exchange transfusion. *Pediatrics* 1985; 75: 417-21.
- Patra K, Storfer-Isser A, Siner B, Moore J, Hack M. Adverse events associated with neonatal exchange transfusion in the 1990s. *J Pediatr* 2004; 144: 626-31. [Crossref]
- Erdeve O, Okulu E, Olukman O, et al; Turkish Neonatal Jaundice Registry Collaborators. The Turkish Neonatal Jaundice Online Registry: A national root cause analysis. *PLoS One* 2018; 13: e0193108. [Crossref]
- Coban A, Turkmen M, GURSOY T. Turkish Neonatal Society guideline to the approach, follow-up, and treatment of neonatal jaundice. *Turk Arch Pediatr* 2018; 25: 172-9. [Crossref]
- Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. *Semin Fetal Neonatal Med* 2008; 13: 207-14. [Crossref]
- Sasmaz I. Glucose-6-phosphate dehydrogenase deficiency. *Turk Arch Pediatr* 2009; 44: 35-8.
- Sarkar S, Rosenkrantz TS. Neonatal polycythemia and hyperviscosity. *Semin Fetal Neonatal Med* 2008; 13: 248-55. [Crossref]
- Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. *Pediatr Clin North Am* 1986; 33: 179-201. [Crossref]
- Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). *J Perinatol* 2009; 29: 25-45. [Crossref]
- Ives NK. Management of neonatal jaundice. *Paediatr Child Health* 2011; 21: 270-6. [Crossref]
- Sgro M, Kandasamy S, Shah V, Ofner M, Campbell D. Severe neonatal hyperbilirubinemia decreased after the 2007 Canadian Guidelines. *J Pediatr* 2016; 171: 43-7. [Crossref]
- Ip S, Chung M, Kulig J, O'Brien R, Sege R, Glicken S, et al; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. *Pediatrics* 2004; 114: e130-53. [Crossref]
- Neonatal jaundice. National Collaborating Centre for Women's and Children's Health (UK). London: RCOG Press. National Institute for Health and Clinical Excellence: Guidance; 2010.
- Sgro M, Campbell D, Shah V. Incidence and cause of severe neonatal hyperbilirubinemia in Canada. *CMAJ* 2006; 175: 587-90. [Crossref]
- Hakan N, Zenciroglu A, Aydin M, Okumus N, Dursun A, Dilli D. Exchange transfusion for neonatal hyperbilirubinemia: an 8-year single center experience at a tertiary neonatal intensive care unit in Turkey. *J Matern Fetal Neonatal Med* 2015; 28: 1537-41. [Crossref]
- Badiee Z. Exchange transfusions in neonatal hyperbilirubinemia: experience in Isfahan, Iran. *Singapore Med J* 2007; 48: 421-3.
- Davutoglu M, Garipardic M, Guler E, Karabiber H, Erhan D. The etiology of severe neonatal hyperbilirubinemia and complications of exchange transfusion. *Turk J Pediatr* 2010; 52: 163-6.
- Altuntas N, Yenicesu I, Himmetoglu O, et al. The risk assessment study for hemolytic disease of the fetus and newborn in a university hospital in Turkey. *Transfus Apher Sci* 2013; 48: 377-80. [Crossref]
- Betran AP, Torloni MR, Zhang J, et al. What is the optimal rate of caesarean section at population level? A systematic review of ecological studies. *Reprod Health* 2015; 12: 57. [Crossref]
- Watt S, Sword W, Sheehan D, et al. The effect of delivery method on breastfeeding initiation from the The Ontario Mother and Infant Study (TOMIS) III. *J Obstetric Gynecol Neonatal Nursing* 2012; 41: 728-37. [Crossref]

29. Regan J, Thompson A, DeFranco E. The influence of mode of delivery on breastfeeding initiation in women with a prior cesarean delivery: a population-based study. *Breastfeeding Med* 2013; 8: 181-6. [\[Crossref\]](#)
30. Bayoumi YA, Bassiouny YA, Hassan AA, Gouda HM, Zaki SS, Abdelrazek AA. Is there a difference in the maternal and neonatal outcomes between patients discharged after 24 h versus 72 h following cesarean section? A prospective randomized observational study on 2998 patients. *J Matern Fetal Neonatal Med* 2016; 29: 1339-43. [\[Crossref\]](#)
31. Braveman P, Egerter S, Pearl M, Marchi K, Miller C. Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: a critical review of the literature. *Pediatrics* 1995; 96: 716-26.
32. Yigit S, Gursoy T, Kanra T, et al. Whole blood versus red cells and plasma for exchange transfusion in ABO haemolytic disease. *Transfus Med* 2005; 15: 313-8. [\[Crossref\]](#)
33. Gharehbaghi MM, Hosseinpour SS. Exchange transfusion in neonatal hyperbilirubinemia: a comparison between citrated whole blood and reconstituted blood. *Singapore Med J* 2010; 51: 641-4.
34. British Committee for Standards in Haematology. Transfusion guidelines for neonates and older children. *Br J Haematol* 2004; 124: 433-53. [\[Crossref\]](#)
35. Kaplan M, Hammerman C. Understanding and preventing severe neonatal hyperbilirubinemia: is bilirubin neurotoxicity really a concern in the developed world? *Clin Perinatol* 2004; 31: 555-75. [\[Crossref\]](#)
36. Shapiro SM, Bhutani VK, Johnson L. Hyperbilirubinemia and kernicterus. *Clin Perinatol* 2006; 33: 387-410. [\[Crossref\]](#)
37. Ebbesen F. Recurrence of kernicterus in term and near-term infants in Denmark. *Acta Paediatr* 2000; 89: 1213-7. [\[Crossref\]](#)
38. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischARGE hour-specific bilirubin measurement for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. *Pediatrics* 1999; 103: 6-14. [\[Crossref\]](#)